Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Gastrointest Endosc. 2018 Sep;88(3):413-426. doi: 10.1016/j.gie.2018.04.2352. Epub 2018 Apr 27.
Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer worldwide, with a high mortality due to advanced stage at diagnosis. Although most common in an area known as the Asian Esophageal Cancer Belt, which extends from the Caspian Sea to northern China, and in parts of Africa, high-risk populations also exist elsewhere in the world. Screening for ESCC has been practiced in a few geographic areas and high-risk populations, with varying levels of success. Esophageal squamous dysplasia is recognized as the precursor lesion for ESCC. Endoscopic screening for ESCC/esophageal squamous dysplasia is expensive and not sufficiently available in many high-risk regions. Recent advances in non-endoscopic screening enhanced by biomarker-based disease detection have raised the prospect of improved accuracy and availability of screening for esophageal squamous dysplasia and early stage ESCC. Development of a cost-effective, accurate, and well-tolerated screening test, if applied in endemic areas and high-risk populations, has the potential to reduce mortality from this deadly disease worldwide. In this review, we summarize recent developments in endoscopic and non-endoscopic screening modalities.
食管鳞状细胞癌(ESCC)是全球最常见的食管癌类型,由于诊断时已处于晚期,死亡率较高。尽管这种癌症在被称为亚洲食管癌带的一个地区最为常见,该地区从里海延伸到中国北方,以及非洲的一些地区,但在世界其他地方也存在高危人群。在一些地理区域和高危人群中已经开展了 ESCC 的筛查,但成功率不一。食管鳞状上皮内瘤变被认为是 ESCC 的癌前病变。ESCC/食管鳞状上皮内瘤变的内镜筛查费用昂贵,在许多高危地区也无法充分普及。最近,基于生物标志物的疾病检测技术的非内镜筛查方法取得了进展,提高了食管鳞状上皮内瘤变和早期 ESCC 筛查的准确性和可用性。如果在流行地区和高危人群中应用一种具有成本效益、准确性高且耐受性良好的筛查试验,有可能降低这种致命疾病的全球死亡率。在这篇综述中,我们总结了内镜和非内镜筛查方法的最新进展。